photo free

Home Images Vectors Videos

Stock image United States - december, 16, 2021 Pfizers Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89 in Interim Analysis of Phase 23 EPIC-HR Study

Stock image United States - december, 16, 2021 Pfizers Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89 in Interim Analysis of Phase 23 EPIC-HR Study

Published: Jan.04, 2022 13:23:45

Author: Giovanni_Cancemi

Views: 0

Downloads: 1

File type: image / jpg

File size: 7.05 MB

Orginal size: 4720 x 4558 px

Available sizes:

S

(500 x 483)

M

(1000 x 966)

L

(2000 x 1931)

XL

(4720 x 4558)

EL0

(4720 x 4558)

Level: silver

Download Image

Image topics:

Similar stock images

stock image United States - december, 16, 2021 Pfizers Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89 in Interim Analysis of Phase 23 EPIC-HR Study

United States - December, 16, 2021 Pfizers Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89 In Interim Analysis Of Phase 23 EPIC-HR Study

4700 × 4200

stock image United States - december, 16, 2021 Pfizers Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89 in Interim Analysis of Phase 23 EPIC-HR Study

United States - December, 16, 2021 Pfizers Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89 In Interim Analysis Of Phase 23 EPIC-HR Study

4720 × 4558

stock image United States - december, 16, 2021 Pfizers Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89 in Interim Analysis of Phase 23 EPIC-HR Study

United States - December, 16, 2021 Pfizers Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89 In Interim Analysis Of Phase 23 EPIC-HR Study

4720 × 4550

stock image United States - december, 16, 2021 Pfizers Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89 in Interim Analysis of Phase 23 EPIC-HR Study

United States - December, 16, 2021 Pfizers Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89 In Interim Analysis Of Phase 23 EPIC-HR Study

4700 × 4200

stock image Bucharest, Romania - February 1, 2022: Illustrative editorial concept image of oral antiviral drug pill Paxlovid developed by Pfizer. Corona virus Covid-19 treatment.

Bucharest, Romania - February 1, 2022: Illustrative Editorial Concept Image Of Oral Antiviral Drug Pill Paxlovid Developed By Pfizer. Corona Virus Covid-19 Treatment.

6367 × 4245

stock image New York, USA - 08 November 2020. Concept of antiviral pill against coronavirus disease. COVID drugs on a medical glass table. Selective focus

New York, USA - 08 November 2020. Concept Of Antiviral Pill Against Coronavirus Disease. COVID Drugs On A Medical Glass Table. Selective Focus

4442 × 2961

stock image Bucharest, Romania - February 1, 2022: Illustrative editorial concept image of oral antiviral drug pill Paxlovid developped by Pfizer. Corona virus Covid-19 treatment.

Bucharest, Romania - February 1, 2022: Illustrative Editorial Concept Image Of Oral Antiviral Drug Pill Paxlovid Developped By Pfizer. Corona Virus Covid-19 Treatment.

4061 × 6091

stock image New York, USA - 08 November 2020. Concept of antiviral pill against coronavirus disease. COVID drugs on a medical glass table. Selective focus

New York, USA - 08 November 2020. Concept Of Antiviral Pill Against Coronavirus Disease. COVID Drugs On A Medical Glass Table. Selective Focus

5472 × 3648